Biogroup bonus drug reduced mortality by 70% in Corona patients

by time news

Company Biograph bonus Published today (Wednesday) the full results of an experiment it conducted on 50 corona patients who were hospitalized in critical condition. According to company reports, 47 of them were still alive about 30 days from the start of treatment. Following the announcement, the company’s share rises 4.6% and the company is traded at a value of NIS 1.56 billion.

The experimental results in this group were compared retrospectively to a control group. In front of each of the first 30 participants in the trial, two severely ill patients with similar characteristics were selected who were not part of the trial and were not treated with a bonus product. This is a partially controlled trial (there is no certainty that the patients who participated in the trial had the same disease characteristics as those who did not participate, and the doctors also knew which patients participated in the trial and which did not). However, given this limitation, the results are impressive: in this group of patients, 14 patients died, compared with only two of the first thirty patients in a bonus trial. For whom the comparison was made. This is an efficiency of 70%.

In addition, the bonus drug shortened the duration of hospitalization of patients by an average of 8 days, compared with the control group, a difference that was found statistically significant. About one-third of corona patients treated with the bonus drug were discharged from the hospital the same day, half were discharged up to one day after treatment and 60% up to two days after treatment.

READ Also:  Covid and pregnancy, "may increase the risk of premature birth. You have to get vaccinated »-

The area of ​​care for the critically ill patients in Corona is the one with the fewest solutions on the market

The field of care for the critically ill patients in Corona is the field in which there are currently few approved marketing solutions. Vaccines prevent the disease or make it a serious disease in the majority of the population, but there is still morbidity among the unvaccinated and exceptional severe cases among the vaccinated, especially in the two-dose vaccine, and it is not known how long the protection will last through the third dose. Patients who are diagnosed quickly can be treated with new drugs, developed by the companies Pfizer, Mark and AstraZeneca, and they reduce the risk of deterioration if given a few days after infection. There is still not much experience in using these products in the real world, and even after using them, there are still patients who continue to deteriorate. The more widespread the epidemic, the more difficult it is to reach and treat these patients in real time, and severe coronary heart disease patients are expected to continue to be hospitalized in the foreseeable future.

There are currently several treatments approved for them: Giliad’s antiviral drug Ramadsiber, anticonvulsants (a treatment whose effectiveness in its current version has been questioned) and antibodies produced in the laboratory. None of these products are considered a “game changer” in the treatment of a serious illness. If the results of Bonus are reproduced in a larger and fully controlled trial, its product may be a significant competitor in the field. Apparently, one more trial in a few hundred to thousands of patients will suffice to examine the issue as long as the results are similar.

READ Also:  "No terrorism on variants, but vaccinate"

Bonus is developing stem cell-based therapies and its products from before the Corona period are still in initial trials and have not yet hit the market, so the company is not recording revenue. The company has NIS 80 million in cash.

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.